Mydecine Innovations Group cultivating low-cost psilocybin mushrooms at scale to treat PTSD

← Back to all news
March 4, 2021

Published at

Mydecine Innovations Group (CSE:MYCO) (OTCMKTS:MYCOF) CEO Joshua Bartch tells Proactive the Colorado-based emerging biotech and life sciences company is advancing towards a Phase 2 study to treat PTSD with its 'purified' psilocybin mushrooms.

Bartch says the group recently produced its first commercial harvest of 20 kilograms of psilocybin mushrooms at a private research and cultivation facility in Jamaica, which was exported into Canada at the University of Alberta.

Watch video below: